CRSP – CRISPR Therapeutics AG

CRISPR Therapeutics AG

CRSP

$37.22

Name : CRISPR Therapeutics AG

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,214,456,832.00

EPSttm : -4.49

CRISPR Therapeutics AG

$37.22

0.98%

$0.37

Float Short %

25.75

Margin Of Safety %

Put/Call OI Ratio

0.57

EPS Next Q Diff

EPS Last/This Y

-0.81

EPS This/Next Y

0.97

Price

37.22

Target Price

78.2

Analyst Recom

1.87

Performance Q

-6.06

Relative Volume

0.9

Beta

1.78

Ticker: CRSP

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	CRSP	38.81	0.52	0.61	116832
2025-04-15	CRSP	38.93	0.53	0.89	122557
2025-04-16	CRSP	37.79	0.56	0.54	135626
2025-04-17	CRSP	37.79	0.56	0.62	135976
2025-04-18	CRSP	37.77	0.56	0.82	135976
2025-04-21	CRSP	37.8	0.60	0.14	117430
2025-04-22	CRSP	39.38	0.59	0.15	119398
2025-04-23	CRSP	38.54	0.57	0.27	121587
2025-04-24	CRSP	39.1	0.57	0.71	122643
2025-04-25	CRSP	38.27	0.57525874319345	0.59616223288269	125263
2025-04-28	CRSP	37.88	0.58899001799609	0.59259259259259	122732
2025-04-29	CRSP	37.4	0.59	0.70	124082
2025-04-30	CRSP	38.63	0.59	0.23	124464
2025-05-01	CRSP	37.93	0.58	0.26	126640
2025-05-02	CRSP	38.22	0.57	0.21	128051
2025-05-05	CRSP	37.57	0.58	1.65	124087
2025-05-06	CRSP	33.15	0.59	1.10	125525
2025-05-07	CRSP	34.25	0.60	0.32	131554
2025-05-08	CRSP	36.12	0.60	0.27	134280
2025-05-09	CRSP	35.61	0.60	0.29	135687
2025-05-12	CRSP	37.58	0.58	0.32	130215
2025-05-13	CRSP	37.26	0.57	0.54	131669
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	CRSP	38.81	12.4	135.4	-4.82
2025-04-15	CRSP	38.95	12.4	124.5	-4.82
2025-04-16	CRSP	37.79	12.4	147.3	-4.86
2025-04-17	CRSP	37.77	12.4	127.1	-4.86
2025-04-18	CRSP	37.77	12.4	127.0	-4.91
2025-04-21	CRSP	37.81	12.0	126.3	-4.91
2025-04-22	CRSP	39.23	12.0	100.8	-4.91
2025-04-23	CRSP	38.54	12.0	138.7	-4.91
2025-04-24	CRSP	39.11	10.7	116.7	-4.99
2025-04-25	CRSP	38.27	10.7	141.4	-4.99
2025-04-28	CRSP	37.88	10.7	133.9	-4.99
2025-04-29	CRSP	37.40	10.7	135.7	-4.96
2025-04-30	CRSP	38.67	10.7	103.0	-4.96
2025-05-01	CRSP	37.69	10.7	144.3	-4.96
2025-05-02	CRSP	38.25	10.7	117.2	-4.96
2025-05-05	CRSP	37.62	10.7	138.3	-4.96
2025-05-06	CRSP	33.15	10.7	210.5	-4.96
2025-05-07	CRSP	34.25	10.7	100.0	-4.96
2025-05-08	CRSP	36.14	13.7	83.6	-4.96
2025-05-09	CRSP	35.63	11.7	144.6	-5.15
2025-05-12	CRSP	37.59	11.7	95.0	-5.15
2025-05-13	CRSP	37.22	11.7	141.3	-5.15
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	CRSP	-3.44	2.97	24.87
2025-04-15	CRSP	-3.44	2.97	24.87
2025-04-16	CRSP	-3.30	2.97	24.87
2025-04-17	CRSP	-3.30	2.97	24.87
2025-04-18	CRSP	-3.30	2.97	24.87
2025-04-21	CRSP	-3.30	2.78	24.87
2025-04-22	CRSP	-3.30	2.78	24.87
2025-04-23	CRSP	-3.30	2.78	24.87
2025-04-24	CRSP	-3.30	2.78	24.87
2025-04-25	CRSP	-3.30	2.78	24.87
2025-04-28	CRSP	-3.30	2.85	25.18
2025-04-29	CRSP	-3.30	2.85	25.18
2025-04-30	CRSP	-3.30	2.85	25.13
2025-05-01	CRSP	-3.30	2.85	25.13
2025-05-02	CRSP	-3.30	2.85	25.13
2025-05-05	CRSP	-3.30	8.20	25.13
2025-05-06	CRSP	-3.30	8.20	25.13
2025-05-07	CRSP	-3.45	8.20	25.08
2025-05-08	CRSP	-3.45	8.20	25.08
2025-05-09	CRSP	-3.45	8.20	25.08
2025-05-12	CRSP	-3.45	7.64	25.75
2025-05-13	CRSP	-3.45	7.64	25.75
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-1.32

Avg. EPS Est. Next Quarter

-1.25

Insider Transactions

-3.45

Institutional Transactions

7.64

Beta

1.78

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

83.1

Max Drawdown 5-Year %

-85.1

Target Price

78.2

P/E

Forward P/E

PEG

P/S

85.33

P/B

1.76

P/Free Cash Flow

EPS

-4.52

Average EPS Est. Cur. Y

-5.15

EPS Next Y. (Est.)

-4.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1023.64

Relative Volume

0.9

Return on Equity vs Sector %

-44.8

Return on Equity vs Industry %

-27.8

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.33

EBIT Estimation

141.3

CRISPR Therapeutics AG

Sector: Healthcare

Industry: Biotechnology

Employees: 393

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

stock quote shares CRSP – CRISPR Therapeutics AG Stock Price stock today

news today CRSP – CRISPR Therapeutics AG stock forecast ,stock prediction 2023 2024 2025

marketwatch CRSP – CRISPR Therapeutics AG yahoo finance google finance

stock history CRSP – CRISPR Therapeutics AG invest stock market

stock prices CRSP premarket after hours

ticker CRSP fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

CRSP – CRISPR Therapeutics AG

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CRSP

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y